Novo Hit With Another Monopoly Suit Over Prandin

Law360, New York (July 14, 2010, 5:59 PM EDT) -- Novo Nordisk A/S has once again been hit with accusations that it manipulates the U.S. Food and Drug Administration's generics approval process as part of an alleged scheme to stunt competition by retaining its monopoly over intellectual property rights to its diabetes drug Prandin.

Faced with losing market exclusivity for the drug's active ingredient repaglinide, Novo Nordisk falsely expanded the use code for one of its repaglinide patents, making it easier for companies to infringe, generic-drug maker Paddock Laboratories Inc. says in a complaint lodged Tuesday...
To view the full article, register now.